Abstract
AIMS Previous investigations on clarifying the metformin’s effect on blood pressure (BP) and hypertension provided inconsistent results. To evaluate the association of the genetically proxied effect of metformin drug targets on BP and risk of hypertension through a drug-target Mendelian Randomization (MR) analysis.
METHODS 32 instrumental variables for five metformin targets (i.e., AMP-activated protein kinase (AMPK), growth differentiation factor 15 (GDF15), mitochondrial glycerol 3 (MG3), Mitochondrial complex I (MCI) and glucagon (GCG)) were introduced to the MR analysis on the outcome datasets of hypertension, systolic and diastolic blood pressure (SBP and DBP). The meta-analyses were conducted to acquire the general effect of the genetically proxied metformin use on hypertension risk and blood pressure.
RESULTS The MR analyses demonstrated that the MCI- and MG3-specific metformin’s use would significantly reduce SBP, DBP, and the risk of hypertension. The meta-analyses showed that the genetically proxied metformin’s use equivalent to a 6.75 mmol/mol reduction on HbA1c could decrease both the SBP (Beta=-1.05, P <0.001) and DBP (Beta=-0.51, P=0.096). Furthermore, metformin’s use was also implied to reduce the risk of hypertension in two independent cohorts.
CONCLUSIONS Metformin use may reduce blood pressure and hypertension risk. The MG3- and MCI-dependent metformin’s effect may play key roles in the anti-hypertension function.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No fund was obtained for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
They have identified 32 instrumental variables for five primary drug targets (i.e., AMP-activated protein kinase (AMPK), growth differentiation factor 15 (GDF15), mitochondrial glycerol 3 (MG3), Mitochondrial complex I (MCI) and glucagon (GCG)) and 23 associated genes of metformin. (see Figure 1. and supplementary Table 7A of Zheng et al (Zheng et al. Diabetologia. 2022). The GWAS datasets for hypertension were acquired from two independent cohorts. Hypertension cohort 1 came from the UK biobank and contained 462933 participants (119731 hypertension patients and 343202 healthy controls). Hypertension cohort 2 derived from the Finnish biobank project FinnGen (https://www.finngen.fi/fi). Its sample size was 218754, with 55917 being hypertension patients and 162837 being healthy controls. Their GWAS summary statistics data were acquired through the platform of the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/datasets, GWAS ID: 'ukb-b-14057', 'finn-b-I9_HYPTENS').
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Lead contact Zenan Lin, MD, Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China., Email: zenan.lin{at}shgh.cn or zenanlin{at}foxmail.com
Data Availability
The used GWAS data were publicly available and their origins were described appropriately in the manuscript. The detailed information and codes required to reanalyse the data in this work are available from the corresponding authors upon reasonable request.
